University of Manchester
Manchester, Greater Manchester, M13 9PT, United Kingdom
NCT Number: NCT02226042
This research will investigate the neuropsychological mechanisms underlying the eight-week Mindfulness-based Cognitive Therapy (MBCT) programme.
Participants in remission from depression will be seen pre- and post-MBCT to assess the underlying neuropsychological mechanisms. All will be followed-up over 12 months to assess the relationship of these neuropsychological changes with relapse risk.
The research will focus primarily on changes in self-compassion, rumination, attention and structural brain changes, with secondary focus on other mechanisms of emotional processing and memory.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Manchester, Greater Manchester, M13 9PT, United Kingdom
There will be three groups in total.
Research visits for participants not undergoing MBCT will be separated by an 8 week gap.
All participants will be seen before and after the 8 weeks for completion of neuropsychological assessments and questionnaires.
rMDD participants will be followed up over the following 12 months to identify any predictors of relapse.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participants with remitted depression (rMDD):
Healthy volunteers:
All participants:
Exclusion criteria
MBCT: Mindfulness-based Cognitive Therapy is an 8 week group-based programme consisting of approximately 12 participants per group. There is also a full one day of practice around week 6. MBCT was initially designed for individuals in remission from depression and at risk of relapsing. The intervention is a mix of mindfulness meditation, cognitive behavioural therapy exercises and psychoeducation. MBCT has been shown to be effective in reducing relapse risk over 12 months.
Other names: MBCT
Time frame: measured at baseline and post intervention (8 weeks post baseline) and at each follow-up visit (3 in total)
Two neuropsychological measures of self-compassion have been developed and will be administerat baseline and after MBCT/8 week gap (8 weeks post baseline). Self-report questionnaires will be administered before and after MBCT/8 week gap and at subsequent follow-up visits (3, 6, 12 months).
Time frame: measured at baseline and after the intervention/8 week gap (8 weeks post baseline) and at each follow-up visit (3 in total)
One neuropsychological measure of rumination has been developed and will be administered at baseline and immediately after MBCT/8 week gap (8 weeks post baseline).
Self-report questionnaires will be administered at baseline and after MBCT/8 week gap (8 weeks post baseline) and at subsequent follow-up visits (3,6,12 months).
Time frame: measured at baseline and after the intervention/8 week gap (8 weeks post baseline)
Time frame: measured at baseline and after the intervention (8 weeks post baseline)
Time frame: measured at baseline and after the intervention/8 week gap (8 weeks post baseline)
Other neuropsychological assessments of emotional processing (face emotion recognition, memory, cognitive flexibility) will be assessed at baseline and after MBCT/8 week gap (8 weeks post baseline).
University of Manchester
Other
Investigating the Neuropsychological Mechanisms Underlying Mindfulness-based Cognitive Therapy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04276259
Behavior, Behavioral Symptoms
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06001346
Behavior, Behavioral Symptoms
Ames, Iowa, United States
View Trial DetailsNCT07101120
Depressive Disorder, Depressive Disorder, Major
Beijing, China
View Trial DetailsNCT05497414
Depressive Disorder, Depressive Disorder, Major
Boston, Massachusetts, United States
View Trial Details